

Biographical Sketch – Dr. Babita Kataria

NAME Babita Kataria	POSITION TITLE Assistant Professor		
INSTITUTION National Cancer Institute-AIIMS,Jhajjar			
EDUCATION / TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
1. Lady Hardinge Medical College, New Delhi, Delhi	MBBS	2008	Basic pre-clinical and clinical
2. Maulana Azad Medical College, New Delhi, Delhi	MD	2015	General Medicine
3. All India Institute of Medical Sciences, New Delhi	DM	2020	Medical Oncology

A. Work Information

Lady Hardinge Medical College and associated hospitals, New Delhi, Delhi	Other training	01/2009- 12/2009	Clinical Internship
Lady Hardinge Medical College & associated hospitals, New Delhi, Delhi	Resident	01/2010- 06/2010	Junior resident (non-academic), Emergency Medicine
Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, Delhi	Resident	01/2011- 02/2011	Junior resident (non-academic), Medical Oncology
Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi	Resident	05/2015- 08/2015	Senior Resident (non-academic), Medical Oncology
Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences, New Delhi, Delhi	Resident	09/2015- 12/2016	Senior Resident (non-academic), Medical Oncology
National Cancer Institute, All India Institute of Medical Sciences, Jhajjar (under AIIMS, New Delhi)	Assistant Professor (ad hoc)	04/2020-11/2022	Assistant Professor (ad hoc), Medical Oncology
National Cancer Institute, All India Institute of Medical Sciences, Jhajjar (under AIIMS, New Delhi)	Assistant Professor (tenured)	28/11/2022- Present	Assistant Professor(tenured), Medical Oncology

B. Awards and honors

2024	Dr. Edward Kennedy Memorial Award , World Cancer Congress 2024, New Delhi, India
2024	ESMO-ICF Clinical unit visit fellowship 2024 , European Society of Medical Oncology- International Cancer Foundation
2024	Young Investigator Travel Award (GCIC CCCC-CR, Gynecologic Cancer Inter GRoup
2024	Mentee- ESMO Virtual Mentorship Programme 2024 , European Society of Medical Oncology
2022	Outstanding young clinician award 2022 , Venus International Healthcare
2022	International Developing Nations Travel Award , European Society of Medical Oncology
2019	Young investigator grant , Society of Hematologic Oncology (SOHO)
2008	Proficiency in surgery, Lady Hardinge Medical College
2007	Proficiency in ophthalmology, Lady Hardinge Medical College
2005	Sh. N.M.Gupta award (Gold Medal, Anatomy), Lady Hardinge Medical College
2005	Proficiency in anatomy practical, Lady Hardinge Medical College

2004	certificate of excellence for excellent performance in academics and best student award, Triveni memorial sr. Sec. School
2004	certificate of merit for securing 90.4% in class XII, CBSE 2004, Rajasthan seva samiti
2004	Kalpna Chawla award -2003-2004 for outstanding performance in AISSCE 2004, Non-profit organisation
2004	Dr.Ambedkar scholarship for first position at stae level in CBSE 2002, Government of State of Haryana

Other achievements:

- 1). Topped exit exam of D.M., Medical Oncology, Dec 2019, AIIMS, New Delhi
- 2). AIIMS D.M. Medical Oncology, All India level entrance examination, November 2016- Rank 1
- 3). National Talent Search Examination (NTSE) 2002 scholar. Only 1000 students are selected annually across the nation.
- 4). Passed national standard examination in biology NSEB 2003 & qualified to appear for the Indian National Biology Olympiad [theory] 2004.

C. Selected publications (in chronological order). For publicly available citations, URLs or PMC submission identification numbers may accompany the full reference.

1. 967: Bone marrow sparing extended field CRT with ddNACT in Stage IIIC2 carcinoma cervix: a phase II study. N Das, SK Saini, DN Sharma, K Kamboj, S Khurana, S.A. Shamim, Raja Pramanik, Dhanabalan Rajasekaran, **Babita Kataria**, Danda Vamsi Sai Praveen, Swayamjeet Sathapathy. Radiotherapy and Oncology, 2024
2. Manav N, Jit BP, **Kataria B**, Sharma A. Cellular and epigenetic perspective of protein stability and its implications in the biological system. Epigenomics. 2024 June; :1-22.
3. Khan S, Das A, Vashisth D, Mishra A, Vidyarthi A, Gupta R, Begam N, **Kataria B**, Bhatnagar S. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales. PLOS ONE. 2024-5-; 19(5): e0303753-. doi: 10.1371/journal.pone.0303753.
4. Khan S, Kharchandy H, **Kataria B***. Metronidazole Refractory Giardiasis Complicating the Management of Rhabdomyosarcoma in a Child. Journal of Antimicrobial Stewardship Practices and Infectious diseases. 2024 March; 2(1):15-19. doi: 10.62541/jaspi017.
5. Khan S, Das A, **Kataria B**, Yadav H, Mirdha BR. Nitazoxanide refractory cryptosporidiosis complicating Burkitt lymphoma in a child. Trop Parasitol. 2024 Jan-Jun;14(1):50-53. doi: 10.4103/tp.tp_25_23. Epub 2024 Feb 15. PubMed PMID: 38444792; PubMed Central PMCID: PMC10911182.
6. Sharma V, Kumar A, Baa A, Kirar S, Sharma A, Bakhshi S, Gogia A, Malik PS, Rastogi S, Batra A, Pushpam D, **Kataria B**, Sagiraju H, Sharma A, Singh V. Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study. BMJ Support Palliat Care. 2024 Jan 8;13(e3): e867-e871. doi: 10.1136/spcare-2022-003864. PubMed PMID: 36927873.
7. Ravindra SG, Pathak J, Khan D, Garg S, Khurana A, Das KJ, **Kataria B**. Unusual Male Breast Involvement in Burkitt Lymphoma Detected on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Indian J Nucl Med. 2023 Jul-Sep;38(3):301-302. doi: 10.4103/ijnm.ijnm_8_23. Epub 2023 Oct 10. PubMed PMID: 38046971; PubMed Central PMCID: PMC10693359.
8. Vidyarthi A, Khan S, **Kataria B**, Nandal M, Phogat V, Das A, Chaudhry R. Chryseobacterium Bloodstream Infection in a Case of Non-Hodgkins Lymphoma: An Emerging Pathogen Complicating Clinical Management in Cancer Patients. Journal of Pure and Applied Microbiology. 2023-9-; 17(3):1422-1428. doi: 10.22207/JPAM.17.3.05.
9. BM M, kumar A, Batra A, Sharma V, **Kataria B**, Gogia A, Mathur S, Sharma A. Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH). American Society of Clinical Oncology; 2023. 0732-183X.

10. Kumar A, Baghmar S, Mehta P, Tiwari P, Kumar L, Bakhshi S, Agarwal A, Gupta I, Trikha A, Bhatnagar S, Gogia A, Malik PS, Sahoo RK, Rastogi S, Pramanik R, Batra A, Pushpam D, Sharma CK, Sharma V, **Kataria B**, Goyal K, Samaga S, Bothra SJ, Sharma A. Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from India. *Indian J Med Res.* 2022 May-Jun;155(5&6):546-553. doi: 10.4103/ijmr.ijmr_1703_21. PubMed PMID: 36348601; PubMed Central PMCID: PMC9807197.
11. **Kataria B**, Sharma A, Pramanik R, Sahoo R, Thulkar S, Yadav M, Mishra S, Prasad C, Vishnubhatla S. PD-9 Three-arm phase II/III randomized controlled trial in patients with unresectable/metastatic gall bladder cancer with poor performance status: Erlotinib or capecitabine v/s best supportive care. *Annals of Oncology.* 2022; 33: S242.
12. Bhargave S, Kumar A, Sharma V, **Kataria B**, Pushpam D, Batra A, Pramanik R, Khurana S, Sahoo R, Malik P. Olanzapine versus fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC \geq 4) containing chemotherapy regimen: A phase 3 randomized, double-blind, placebo-controlled trial. *American Society of Clinical Oncology*; 2022. 0732-183X.
13. Sharma A, **Kataria B**¹, Biswas B, Bakhshi S, Pushpam D. Oral metronomic chemotherapy is a cost-effective alternative to pazopanib in advanced soft tissue sarcoma. *J Oncol Pharm Pract.* 2022 Apr;28(3):560-568. doi: 10.1177/10781552211000113. Epub 2021 Mar 9. PubMed PMID: 33719725.
14. **Kataria B**, Sharma A, Biswas B, Bakhshi S, Pushpam D. Pazopanib in rare histologies of metastatic soft tissue sarcoma. *Ecancermedicalsecience.* 2021; 15:1281. doi: 10.3332/ecancer.2021.1281. eCollection 2021. PubMed PMID: 34824604; PubMed Central PMCID: PMC8580588.
15. Prasad KT, Muthu V, Biswas B, Malik PS, Dabkara D, Ganguly S, Ghosh J, **Kataria B**, Khurana S, Verma S, Singh N. Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories: real-world experience. *Curr Probl Cancer.* 2020 Jun;44(3):100565. doi: 10.1016/j.crrproblcancer.2020.100565. Epub 2020 Mar 5. PubMed PMID: 32173058.
16. Kumar L, Ramavath D, **Kataria B**, Tiwari A, Raj A, Chellapuram SK, Mookerjee A, Sahoo RK, Malik PS, Sharma A, Gupta R, Sharma OD, Biswas A, Kumar R, Thulkar S. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. *Indian J Med Res.* 2019 Jun;149(6):730-739. doi: 10.4103/ijmr.IJMR_1593_18. PubMed PMID: 31496525; PubMed Central PMCID: PMC6755776.
17. **Kataria B**^{*}, Sharma A, Mishra S, Bhatnagar S, Thulkar S, Yadav M, Sahoo R, Pramanik R, Prasad C, Sreenivas V. Capecitabine+ best supportive care (BSC) or erlotinib+ BSC has overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT). *Annals of Oncology.* 2019; 30: v279.
18. **Kataria B**^{*}, Upadhyay A, Kumar L. Stop Imatinib: Real World Data from a Tertiary Care Center in India. *Clinical Lymphoma, Myeloma and Leukemia.* 2019; 19: S301.
19. Rastogi S, Aggarwal A, Soti K, Vanidassane I, Sharma M, Yadav A, Sharma A, **Kataria B**, Deo S. Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. *American Society of Clinical Oncology*; 2017. 0732-183X.
20. Kutiya AS, Dharmshaktu P, **Kataria B**, Garg A. A Rare Occurrence of Simultaneous Venous and Arterial Thromboembolic Events - Lower Limb Deep Venous Thrombosis and Pulmonary Thromboembolism as Initial Presentation in Acute Promyelocytic Leukemia. *Clin Med Insights Oncol.* 2016; 10:1-4. doi: 10.4137/CMO.S37866. eCollection 2016. PubMed PMID: 26949347; PubMed Central PMCID: PMC4768938.
21. Dhanwal D, **Kataria B**, Kumar V. Secondary fracture prevention-a New Delhi, India initiative. *OSTEOPOROSIS INTERNATIONAL.* 2013; 24: S60-S60.

D. Research Support. List selected ongoing, completed (during the last three years), and pending research projects (public and private support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project.

Short title of the project	PI/ C o- PI	Funding Agency	Amount of funding	Status
CERvical cancer - role of COnsolidation chemotherapy (CERCO) - A multi-arm, open-label, Phase II randomized non-comparative trial to test the efficacy of consolidation chemotherapy in locally advanced cervical cancer	PI	AIIMS, Delhi	INR 10,00,000/- (Approx. 24000 USD)	Funding secured Submitted for IRB approval
A phase II RCT to test impact of two different dose levels of maintenance CAPECitabine on progression free survival in patients with persistent/recurrent/metastatic CERVical cancer not progressing on platinum based chemotherapy (CAPE-CERV)	PI	AIIMS, Delhi	INR 20,00,000/- (Approx. 24000 USD)	Funding secured. Submitted for IRB approval.
Phase II/III RCT to compare Erlotinib/Capecitabine with BSC only in Gall bladder cancer patients unfit for chemotherapy.	PI	All India Institute of Medical Sciences (AIIMS), Delhi, India (Intramural)	All investigations and treatments made free for trial patients	Presented at ESMO World Congress on GI cancer 2022, Barcelona Spain With International Developing Nations Travel Award
Phase II RCT to test if olanzapine improves quality of life with palliative chemotherapy	PI	AIIMS, Delhi and IASCC (Indian Association of Supportive Care in Cancer)	All investigations and treatments free for trial patients. INR 4,00,000/-for Consumables (Approx. 4800 USD)	Received Dr. Edward Kennedy Memorial Award for best oral presentation at the 8th World Cancer Congress, New Delhi, India. In pre-publication stage.

E. Other Scientific Activities. List conferences at which you have presented research results, lectured, moderated, etc.

2024	8th World Cancer Congress, New Delhi, India, March 2024	Presented oral abstract for study "Phase II RCT to test if olanzapine improves quality of life with palliative chemotherapy".	Received Dr. Edward Kennedy Memorial Award for best oral presentation
2024	GCIG Spring Meeting 2024	GCIG Brainstorming Session Equity, Diversity and Inclusion in Clinical Research	Actions to increase patient numbers from vulnerable groups in clinical trials (patients in poverty, patients with language barriers, patients from LMIC etc.), e.g. questionnaires in different languages. Drafting up to 5 Statements
2022	ESMO World Congress on GI cancer 2022, Barcelona, Spain	Poster discussion for our study- "Phase II/III RCT to compare Erlotinib/Capecitabine with BSC only in Gall bladder cancer patients unfit for chemotherapy."	International Developing Nations Travel Award
2019	Society of Hematologic Oncology Annual Meeting 2019	Poster presentation- "Stop Imatinib: Real World Data from a Tertiary Care Center in India."	Young investigator grant
2019	ESMO 2019 Congress, Barcelona, Spain.	Poster presentation- "Capecitabine +Best supportive care (BSC) or Erlotinib +BSC has Overall survival (OS) benefit over BSC alone in unresectable/metastatic Gall bladder cancer(GBC) patients with ECOG PS-III. Results from a phase II Randomised controlled trial (RCT)"	
2013	ESCEO 13-IOF, Rome, Italy	Poster presentation- "Role of structured intervention in fragility hip fracture: Secondary fracture prevention."	

F. Other Professional Activities. List the professional societies you belong to, positions you currently hold (or held in the past) with organizations, etc.

2024 - Member, European Society of Gynaecological Oncology
2024 - Member, International Gynecologic Cancer Society, GA
2024 - Member, Indian Cooperative Oncology Network
2023 - Member, Kolkata Gynae-onco Translational research Group, Kolkata
2022 - Member, American Society of Clinical Oncology, VA
2022 - 2023 Member, International Association for the Study of Lung Cancer, CO
2019 - Member, European Society of Medical Oncology, Lugano
2019 - Member, Society of Hematologic Oncology, TX